MDACC Study No:2010-0570LEUKEMIA ( NCT No: NCT01592136)
Title:Expanded Access Program of Ponatinib (AP24534) for Patients with Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Principal Investigator:Jorge Cortes
Treatment Agent:Ponatinib
Study Status:Closed
Study Description:This is a multicenter expanded access program of oral ponatinib in patients
with CML and Ph+ ALL who have not responded to other treatments. A minimal
amount of data will be collected to check the safety of treatment with

The goal of this program is to provide you the opportunity to receive access to
the investigational drug ponatinib.

Ponatinib is designed to interfere with proteins in cancer cells that may cause
different blood cancers. It is also designed to interfere with a certain
genetic mutation, called the T315I mutation, that many patients with leukemia
have. Blocking these proteins and/or this mutation may cause the cancer to
stop growing.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Ponatinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Ariad Pharmaceuticals, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults